{"status":"OK","data":{"advertisement":{"id":241733,"title":"Request for Quotation no. 19 01 2024 DM - Database for analysis and insight into the latest clinical and market data from the pharmaceutical and biotechnology industries.","partial_offer_allowed":false,"publication_date":"2024-01-19","submission_deadline":"2024-01-26 20:00:00","planned_sign_date":"2024-02-01","supplementary_orders":null,"terms_of_contract_change":"VIII.3.\tThe Ordering Party provides for the possibility of amending the terms of the contract concluded as a result of this procedure:\na.\tin the event of a change in applicable legislation if it becomes necessary to adapt the content of the agreement to the current state of the law (including applicable standards),\nb.\tin the event that the necessity to introduce changes results from changes in the guidelines, recommendations or decisions issued by the Institution which granted the funds for financing the agreement,\nc.\tin the event of a change in the rate of goods tax on a product which is the subject of the agreement, \nd.\textension of the license period - the Ordering Party reserves the option to renew the license for additional years during the duration of the Projects. Before the end of the current license period, the Ordering Party will request the Supplier to send a quote for the following year. The Ordering Party reserves the right to renew the license if the price for the following year is no more than 18% higher than the price for the current year.\ne.\tcontract duration - the Ordering Party reserves the right to amend the expected date of contract execution as a result of changes in the scope of the signed agreement for the co-financing of the Projects (extension of the duration of the Projects or their stages),\nf.\toccurrence of force majeure - the Ordering Party reserves the right to amend the terms of the contract concluded as a result of this procedure also in the event of the occurrence of force majeure understood as an event that substantially impedes the performance of obligations under the grant contract, which the parties could not have foreseen and which they could not have prevented or overcome by acting with due diligence.\ng.\tin the case of conditions in accordance with section 3.2.4. para. 4.b -e. Guidelines on the eligibility of expenditure for the period 2021-2027 para. 4.b -e.","created_at":"2024-01-19 18:10:42","modified_at":"2024-01-26 20:00:03","contact_persons":[{"id":57,"forename":"Aleksandra","surname":"Mazga\u0142a","phone_number":"+48 538 899 945","email":"tenders@ryvu.com","created_by":null,"created_at":"2026-10-08 17:23:16","modified_at":"2026-10-08 17:23:16","modified_by":null}],"orders":[{"id":392197,"estimated_value":null,"order_items":[{"id":442236,"description":"In connection with the implementation of the projects entitled \u2018The conduct of a phase II, multicentre, open-label clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax and a hypomethylating agent\u2019 no. 2022/ABM/06/00002/P/02 co-financed from the state budget by the Medical Research Agency under the Competition: Development of targeted or personalized medicine based on therapeutic products based on nucleic acids and small-molecule compounds no. ABM/2022/6; \u2018Synthetic lethality mechanism based discovery of innovative targeted cancer therapies (SLOnco)\u2019 applying for funding under call no. FENG.01 .01-IP.02-001/23 (application number: FENG.01.01-IP.02-0392/23) as part of the European Funds for Smart Economy programme; \u2018Development of targeted anticancer therapy based on inhibition of WRN helicase (CanSL)\u2019 applying for funding under call no. FENG.01.01-IP.02-002/23 (application number: FENG.01.01-IP.02-2086/23) as part of the European Funds for Smart Economy programme.\n\nPart of the contract: Part 1\nName and CPV code:  48460000-0 Analytical, scientific, mathematical or forecasting software package, 48480000-6 Sales, marketing and Business intelligence software package, 48610000-7 Database systems.\n\nDatabase for analysis and insight into the latest clinical and market data from the pharmaceutical and biotechnology industries.\n\nThe report-style database that covers:\n\u00ad\tOncology market\n\u00ad\tSales forecasts\n\u00ad\tLate-staged (Phase 2b, 3, NDA) drugs and marketed drugs\n\u00ad\tFull drug analyses\n\u00ad\tDrug comparator (commercially and clinically attractive through specific weighting metrics)\n\u00ad\tDisease briefings \n\u00ad\tEpidemiology forecasting (including drug treated cases)\n\u00ad\tUpcoming events tracker and impacted events \n\u00ad\tUpdated at least quarterly\n\nThe drug database that covers:\n\u00ad\tAll therapeutic classes (covers over 80,000 drugs, no duplicates)\n\u00ad\tAll stages of development (pre-clinical to post-marketing, status of active, discontinued, suspended, pipeline)\n\u00ad\tFull scientific drug profile (including chemical structures, targets, MOA, disease status, top line clinical trial information)\n\u00ad\tLicensing availability data  \n\u00ad\tCompetitive intelligence \n\u00ad\tCompany profile\n\u00ad\tUp-to-date regulatory, clinical and commercial events\n\u00ad\tDelivery technology, route and medium\n\u00ad\tUpdated in real-time\n\nUnlimited analysts support, unlimited requests included\nUnlimited training sessions included\nLicense duration: 1 year, with the possibility of renewing the license for additional years during the duration of the Projects\nLicense type/size: at least 5 users\nPLACE OF DELIVERY: the registered office of the Ordering Party. \nDELIVERY TIME: granting of access of the license within max. 7 calendar days from the date of the signing the agreement; \nThe delivery date is an admission condition - bids not meeting the above dates will be rejected.\nPAYMENT TERM: Invoice payment terms of at least 30 calendar days. The payment term is an admission condition \u2013 bids indicating a shorter term will be rejected.\n","warranty_period":null,"cpv_items":[{"id":7257,"code":"48460000-0","name":"Analityczne, naukowe, matematyczne lub prognozuj\u0105ce pakiety oprogramowania"},{"id":7262,"code":"48480000-6","name":"Pakiety oprogramowania dla sprzeda\u017cy, marketingu i wywiadu gospodarczego"},{"id":7281,"code":"48610000-7","name":"Systemy baz danych"}],"timetable_items":[],"fulfillment_places":[{"country":"Polska","voivodeship":"ma\u0142opolskie","poviat":"Krak\u00f3w","commune":"Krak\u00f3w-Podg\u00f3rze","locality":"Krak\u00f3w","created_by":null,"created_at":"2024-01-19 18:10:42","modified_at":"2024-01-19 18:10:42","modified_by":null,"id":495605,"type":{"id":1,"name":"adres"},"group_uuid":"0a81ba9d-a261-462d-8504-13e090dcfe22"}],"participation_conditions":[{"id":1209677,"description":"The evaluation of the conditions for participation in the procedure is carried out according to the meet-not meet system.\nDue to the prohibition of conflicts of interest, Contractors with personal or capital ties to the Ordering Party are excluded from the procedure. Equity or personal relationship is understood as relations between the Ordering Party or individuals authorized to take commitments on behalf of the Ordering Party or those acting on behalf of the Ordering Party in order to prepare and implement the contractor selection procedure, and the Contractor, including in particular:\na.\tparticipation in a company as a partner in a civil law partnership or a partnership, holding at least 10% of shares (unless a lower threshold is specified by law), being a member of a supervisory or managerial body, a proxy, a proxy, \nb.\tthey are married, in a relationship of kinship or affinity in a straight line, or in a relationship of kinship or affinity in the collateral line to the second degree, or in a relationship of adoption, custody or guardianship, or in a shared life relationship with the economic operator, its legal deputy, or members of the management or supervisory bodies of contractors applying for the award of the contract, \nc.\tthey have such a legal or factual relationship with the economic operator that there is a reasonable doubt as to their impartiality or independence in connection with the contract award procedure.\nAssessment of the fulfillment of the above-mentioned condition will be made on the basis of a declaration of the Ordering Party.","type":{"id":7,"name":"Dodatkowe warunki udzia\u0142u"},"created_by":null,"created_at":"2024-01-19 18:10:42","modified_at":"2024-01-19 18:10:42","modified_by":null,"group_uuid":"daf57a8c-6876-4dd4-b302-a36549768ad8"}],"category":{"id":3,"name":"Dostawa"},"subcategory":{"id":15,"name":"Dostawy inne"},"created_by":null,"created_at":"2024-01-19 18:10:42","modified_at":"2024-01-19 18:10:42","modified_by":null,"group_uuid":"75042826-e952-4681-ace3-3d6349413ab7"}],"evaluation_criteria":[{"id":673374,"price_criterion":true,"description":"Net price (\u2018C\u2019) - weight: 100% (10 points).\nThe net price must cover the sale and delivery/ granting of access of the 1-year license.","created_by":null,"created_at":"2024-01-19 18:10:42","modified_at":"2024-01-19 18:10:42","modified_by":null,"group_uuid":"072e8088-0964-4187-8ea3-c62eba94bf0a"}],"is_variant":false,"title":"Database for analysis and insight into the latest data","order_node":{"id":297544},"created_by":null,"created_at":"2024-01-19 18:10:42","modified_at":"2024-01-19 18:10:42","modified_by":null}],"created_by":{"id":112,"contact_persons":[]},"modified_by":{"modified_by":null,"id":1,"contact_persons":[]},"status":{"id":2,"label":"PUBLISHED","name":"Opublikowane"},"advertiser_address_details":{"name":"RYVU THERAPEUTICS S.A.","identification_number_type":"nip","identification_number":"6792942955","address":{"country":"Polska","voivodeship":"ma\u0142opolskie","poviat":"Krak\u00f3w","commune":"Krak\u00f3w-Podg\u00f3rze","locality":"Krak\u00f3w","created_by":{"id":112,"contact_persons":[]},"created_at":"2024-01-19 18:10:42","modified_at":"2024-01-19 18:10:42","modified_by":{"id":112,"contact_persons":[]},"id":641892,"street":"Sternbacha","number_description":"2","postcode":"30-394"},"created_by":{"id":112,"contact_persons":[]},"created_at":"2024-01-19 18:10:42","modified_at":"2024-01-19 18:10:42","modified_by":{"id":112,"contact_persons":[]},"id":242291},"advertisement":{"id":183946,"number":"2024-112-183946","publication_date":"2024-01-19","created_by":{"id":112,"contact_persons":[]},"created_at":"2024-01-19 18:05:14","modified_at":"2024-01-26 20:00:03","modified_by":{"modified_by":null,"id":1,"contact_persons":[]},"status":{"id":6,"label":"RESOLVED","name":"Rozstrzygni\u0119te"},"all_available_version_ids":[241732,241733],"enrollment":{"id":39917,"name":"Rozw\u00f3j celowanej terapii przeciwnowotworowej opartej o zahamowanie helikazy WRN (CanSL)","number":"002/23","activity":{"created_by":null,"created_at":"2023-02-01 09:22:25","modified_at":"2023-02-01 09:22:25","modified_by":null},"region":null,"institution":{"created_by":null,"created_at":"2023-02-01 09:28:01","modified_at":"2023-02-01 09:28:01","modified_by":null},"full_number":"FENG.01.01-IP.02-002/23","perspective":{},"programme":{"created_by":null,"created_at":"2023-02-01 09:21:41","modified_at":"2023-02-01 09:21:41","modified_by":null},"priority":{"created_by":null,"created_at":"2023-02-01 09:21:51","modified_at":"2023-02-01 09:21:51","modified_by":null},"type":"enrollment","created_by":null,"created_at":"2023-07-17 12:04:06","modified_at":"2023-07-17 12:04:06","modified_by":null},"projects":[],"is_author":false,"is_admin":false},"attachments":[{"origin":{"id":241733,"publication_date":"2024-01-19"},"id":1231321,"name":"RFQ 19 01 2024 DM","file":{"id":1372369,"name":"RFQ 19 01 2024 DM.pdf","created_at":"2024-01-19 18:10:26","created_by":{"forename":"Aleksandra","surname":"Mazga\u0142a"},"uri":"/api/files/1372369"},"group_uuid":"95421593-96fa-4e99-b27a-66f771162efd"},{"origin":{"id":241733,"publication_date":"2024-01-19"},"id":1231322,"name":"Offer form 19 01 2024 DM","file":{"id":1372370,"name":"Offer form 19 01 2024 DM.docx","created_at":"2024-01-19 18:10:35","created_by":{"forename":"Aleksandra","surname":"Mazga\u0142a"},"uri":"/api/files/1372370"},"group_uuid":"f8d8d2b9-d7fd-4bd1-ad79-061af5e3148f"}]},"dictionaries":{"announcement_status_draft":1,"announcement_status_published":2},"favorite":null,"badge":null,"offer_set_badge_count":null,"question_badge_count":null}}